2024-514871-17-00CompletedPhase 1
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE PHASE 1 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, AND PHARMACODYNAMIC PROFILE OF RES-010 IN HEALTHY, OVERWEIGHT, AND MODERATELY OBESE SUBJECTS
Source: EU CTIS (euclinicaltrials.eu) · Last updated 25 Feb 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 20 Jun 2024
- Start date
- 29 Oct 2024
- Lead sponsor
- Resalis Therapeutics S.r.l.
- Diseases
- Obesity
- EU CT number
- 2024-514871-17-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 80
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.